Prevention of Restenosis Following Revascularization
A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis Following Revascularization of the Superficial Femoral Artery (SFA)
Sponsor: Celgene Corporation
Terminated
Study was terminated due to changing sponsor priorities, and was not based on safety or outcomes data.
Other terminated trials from Celgene Corporation
- Multiple Myeloma · Phase PHASE1/PHASE2 · Oct 2025
- Leukemia, Myeloid, Acute · Phase PHASE1 · Jul 2025
- Relapsed/Refractory Multiple Myeloma · Phase PHASE2 · Jul 2025
- Multiple Myeloma · Jun 2025
- Multiple Sclerosis · Phase PHASE3 · May 2025
More terminations from Celgene Corporation
A PHASE2 clinical study on Vascular Disease, Peripheral, this trial is terminated or withdrawn. The trial is conducted by Celgene Corporation and has accumulated 10 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene Corporation
For direct contact, visit the study record on ClinicalTrials.gov .